NO974403L - Reversible proteasehemmere - Google Patents

Reversible proteasehemmere

Info

Publication number
NO974403L
NO974403L NO974403A NO974403A NO974403L NO 974403 L NO974403 L NO 974403L NO 974403 A NO974403 A NO 974403A NO 974403 A NO974403 A NO 974403A NO 974403 L NO974403 L NO 974403L
Authority
NO
Norway
Prior art keywords
protease inhibitors
reversible protease
reversible
inhibitors
protease
Prior art date
Application number
NO974403A
Other languages
English (en)
Other versions
NO311573B1 (no
NO974403D0 (no
Inventor
James T Palmer
David Rasnick
Jeffrey L Klaus
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of NO974403D0 publication Critical patent/NO974403D0/no
Publication of NO974403L publication Critical patent/NO974403L/no
Publication of NO311573B1 publication Critical patent/NO311573B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO19974403A 1995-03-24 1997-09-23 Reversible proteasehemmere NO311573B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40999695A 1995-03-24 1995-03-24
PCT/US1996/003844 WO1996030353A1 (en) 1995-03-24 1996-03-21 Reversible protease inhibitors

Publications (3)

Publication Number Publication Date
NO974403D0 NO974403D0 (no) 1997-09-23
NO974403L true NO974403L (no) 1997-11-17
NO311573B1 NO311573B1 (no) 2001-12-10

Family

ID=23622800

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19974403A NO311573B1 (no) 1995-03-24 1997-09-23 Reversible proteasehemmere

Country Status (15)

Country Link
EP (1) EP0817778A1 (no)
JP (1) JPH11503417A (no)
KR (1) KR19980703261A (no)
CN (1) CN1071751C (no)
AU (1) AU713492B2 (no)
CA (1) CA2216151A1 (no)
CZ (1) CZ298197A3 (no)
IL (1) IL117638A0 (no)
MY (1) MY113489A (no)
NO (1) NO311573B1 (no)
NZ (1) NZ305626A (no)
PL (1) PL322409A1 (no)
TW (1) TW470750B (no)
WO (1) WO1996030353A1 (no)
ZA (1) ZA962336B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0912601T4 (da) 1996-04-22 2009-03-09 Massachusetts Inst Technology Suppression af immunrespons ved inhibering af cathepsin S
NZ333713A (en) * 1996-07-30 2000-12-22 Axys Pharm Inc Compounds for treating diseases associated with tryptase activity
DE19817461A1 (de) * 1998-04-20 1999-10-21 Basf Ag Neue substituierte Benzamide, deren Herstellung und Anwendung
CN1142912C (zh) * 1998-08-04 2004-03-24 阿斯特拉曾尼卡有限公司 用作细胞因子产生的抑制剂的酰胺衍生物
ES2211172T3 (es) * 1998-09-25 2004-07-01 Astrazeneca Ab Derivados de benzamida y su utilizacion como inhibidores de citoquinas.
WO2000051998A1 (en) * 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
NZ518255A (en) * 1999-09-13 2004-11-26 Boehringer Ingelheim Pharma Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
EP1230349B1 (en) 1999-11-18 2007-06-13 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
AU2001281255B2 (en) 2000-08-14 2006-07-20 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
PT1309592E (pt) 2000-08-14 2006-07-31 Ortho Mcneil Pharm Inc Pirazoles substituidos
RU2317988C2 (ru) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
CN1642973A (zh) 2000-09-06 2005-07-20 奥索-麦克尼尔药品公司 治疗变态反应的方法
AU2002232558A1 (en) * 2000-12-12 2002-06-24 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
JP2004523506A (ja) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド カテプシン阻害剤としての新規な化合物と組成物
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
EP1383884A4 (en) 2001-03-22 2004-12-15 Dendreon Corp SERINE PROTEASE CVSP14 CODING NUCLEIC ACID MOLECULES, THE CODED POLYPEPTIDES AND METHODS THEREOF
NZ527971A (en) 2001-03-27 2006-03-31 Dendreon Corp Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
WO2002092841A2 (en) 2001-05-14 2002-11-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
RS19504A (sr) 2001-09-14 2007-02-05 Aventis Pharmaceuticals Inc., Nova jedinjenja i kompozicije kao inhibitori katepsina
WO2003024923A1 (en) * 2001-09-14 2003-03-27 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
HUP0401906A3 (en) 2001-11-14 2008-07-28 Aventis Pharma Inc Novel cathepsin s inhibitors, process for their preparation and pharmaceutical compositions containing them
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
DK2288615T3 (en) * 2008-05-21 2017-09-04 Genesis Tech Ltd SELECTIVE CASPASE INHIBITORS AND APPLICATIONS THEREOF
US9045524B2 (en) 2009-05-21 2015-06-02 Novagenesis Foundation Selective caspase inhibitors and uses thereof
WO2011069149A2 (en) 2009-12-04 2011-06-09 Dcb-Usa Llc Cathepsin s inhibitors
EP2697246B1 (en) 2011-04-15 2018-03-07 Genesis Technologies Limited Selective cysteine protease inhibitors and uses thereof
KR101309578B1 (ko) * 2011-05-06 2013-09-17 연세대학교 산학협력단 시스테인 프로테아제 선택성을 갖는 다이타이로신 화합물 및 이를 이용한 시스테인 프로테아제의 검출방법
KR101385855B1 (ko) * 2012-10-16 2014-04-22 이동익 카뎁신 검출용 다이아로마틱 아미노산 기질
CN111601813A (zh) * 2018-01-19 2020-08-28 株式会社大阪曹达 有机硅化合物及使用了该有机硅化合物的橡胶组合物
EP3553521A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Gingivitis diagnostic methods, uses and kits

Also Published As

Publication number Publication date
TW470750B (en) 2002-01-01
IL117638A0 (en) 1996-07-23
MY113489A (en) 2002-03-30
AU713492B2 (en) 1999-12-02
PL322409A1 (en) 1998-01-19
AU5367496A (en) 1996-10-16
CA2216151A1 (en) 1996-10-03
CZ298197A3 (cs) 1998-03-18
KR19980703261A (ko) 1998-10-15
ZA962336B (en) 1996-07-31
CN1071751C (zh) 2001-09-26
NO311573B1 (no) 2001-12-10
NO974403D0 (no) 1997-09-23
NZ305626A (en) 2000-01-28
WO1996030353A1 (en) 1996-10-03
JPH11503417A (ja) 1999-03-26
EP0817778A1 (en) 1998-01-14
CN1184472A (zh) 1998-06-10

Similar Documents

Publication Publication Date Title
NO974403D0 (no) Reversible proteasehemmere
NO20006717D0 (no) Proteaseinhibitorer
NO975742D0 (no) Reversible cysteinproteasehemmere
NO995433D0 (no) Protease-inhibitorer
PT936912E (pt) Inibidores de cisteina protease
FI965019A7 (fi) Entsyymi-inhibiittoreita
FI962315L (fi) Entsyymi-inhibiittorit
NO932620D0 (no) Amindiol-proteaseinhibitorer
FI963597L (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
FI973282A7 (fi) Trombiinin inhibiittoreita
FI962904L (fi) Metalloproteinaasi-inhibiittoreita
FI962905A7 (fi) Metalloproteinaasi-inhibiittoreita
FI972160A0 (fi) Matriisimetalloproteaasi-inhibiittorit
DK0858464T3 (da) Thrombin-inhibitorer
NO995435D0 (no) Protease-inhibitorer
NO995268D0 (no) Proteaseinhibitorer
NO995434D0 (no) Proteaseinhibitorer
FI972198L (fi) Metalloproteinaasi-inhibiittoreita
DE69431454D1 (de) Amylase Inhibitoren
BR9610514A (pt) Inibidores cicloantihelmínticos
BR9612344A (pt) Inibidores de proteases
MA26429A1 (fr) Inhibiteurs de protease
KR970703937A (ko) 금속단백질 분해효소 억제제(Metallproteinase inhibitors)
CY2007006I2 (el) Αναστολεις συνθεσεις απολιποπρωτεϊνης-β

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN SEPTEMBER 2002